Cipla Ltd, a global pharmaceutical company, has yielded a final approval for its lead MDI product Fluticasone + Salmeterol (Sereflo) from UK MHRA for its partner in the UK.
Sereflo, 25 mcg/125 mcg & 25 mcg/250 mcg are generic equivalent to GlaxoSmithKline’s Seretide Inhalers and are indicated for asthma treatment.
Seretide Inhaler, for the aforementioned strengths, had UK sales of approximately $278M for the 12 month period ending June 2016, according to IMS Health. Cipla’s Sereflo will be launched in the UK through a partner in the coming weeks.
Commenting on the approval Umang Vohra, MD and global CEO Cipla Ltd., said, “We are extremely pleased with the approval of Sereflo in the UK. This is a testament of Cipla’s relentless efforts in the respiratory field for over a decade. This reinforces Cipla’s commitment to make a difference in the life of patients with its innovative products. Sereflo will help patients with moderate to severe asthma breathe better.”